The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance the National Institutes of Health (NIH) mission by utilizing Special Statutory Funding Program for Type 1 Diabetes Research funds to support studies focused on the involvement of the innate immune system in the initiation of Type 1 diabetes (T1D). This initiative directly aligns with the first goal of the congressionally mandated Special Diabetes Program, which is to identify the genetic and environmental causes of T1D. By engaging multidisciplinary teams with expertise in innate immunity and beta-cell biology, the program aims to elucidate how innate immune components interact with pancreatic tissues and beta cells. The program will leverage the use of new approach methodologies (NAMs) to precisely define the timing and impact of environmental perturbations that activate innate immune pathways. Ultimately, these studies may enable earlier identification of individuals at elevated risk for T1D (beyond genetic susceptibility) and lay the groundwork for future prevention and therapeutic strategies. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.

Government

• Public and Indian housing authorities
• County governments
• City or township governments
• State governments
• Federally recognized Native American tribal governments
• Special district governments

Nonprofit

• Other Native American tribal organizations
• Nonprofits non-higher education without 501(c)(3)
• Nonprofits non-higher education with 501(c)(3)

Business

• Small businesses
• For-profit organizations other than small businesses

Education

• Independent school districts
• Private institutions of higher education
• Public and state institutions of higher education

Miscellaneous

• Other